Our View
We expect investor focus to remain on Afrezza going forward. However, we are concerned about the company’s over dependence on Afrezza. Any setback related to the diabetes candidate will be catastrophic for MannKind.
MannKind, a biopharma stock, presently carries a Zacks Rank #3 (Hold). Other biopharma stocks, such as Actelion Ltd. (ALIOF), Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) and Amarin Corporation (AMRN - Snapshot Report) are comparatively well placed. While Actelion carries a Zacks Rank #1 (Strong Buy), Alexion and Amarin carry a Zacks Rank #2 (Buy).
http://www.zacks.com/stock/news/106509/wider-than-expected-loss-at-mannkind
